| Literature DB >> 21611114 |
Hong Zhang1, Qingmei Li, Jie Sun, Chunyan Wang, Qing Gu, Xiangwei Feng, Bing Du, Wei Wang, Xiaodong Shi, Siqi Zhang, Wanyu Li, Yanfang Jiang, Junyan Feng, Shumei He, Junqi Niu.
Abstract
BACKGROUND AND AIM: The prevalence of the hepatitis B virus (HBV) is higher in adults than in children. We determined the seroepidemiology of HBV infection in an adult population in JiLin, China, to guide effective preventive measures.Entities:
Keywords: hepatitis B; immunity; seroepidemiologic study; vaccine.
Mesh:
Substances:
Year: 2011 PMID: 21611114 PMCID: PMC3100740 DOI: 10.7150/ijms.8.321
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Hepatitis B Markers in the Study Population (n=3833)
| Marker | Number | Percent | 95%CI |
|---|---|---|---|
| HBsAg (+) | 168 | 4.38 | 3.74-5.03 |
| Anti-HBs (+) | 1367 | 35.66 | 34.15-37.18 |
| HBeAg (+) | 53 | 1.38 | 1.01-1.75 |
| Anti-HBe (+) | 255 | 6.65 | 5.86-7.44 |
| Anti-HBc (+) | 1567 | 40.88 | 39.33-42.43 |
| HBsAg (+) and HBeAg (+) | 24 | 14.29* | 8.99-19.58 |
HBsAg, hepatitis B surface antigen; anti-HBs, antibody to hepatitis B surface
antigen; HBeAg, hepatitis B e antigen; anti-HBe, antibody to HBeAg; anti-HBc, antibody to hepatitis B core antigen; CI: Confidence interval.
*HBsAg (+) and HBeAg (+) versus HBsAg (+)
Hepatitis B Marker Combinations in the Study Population (n=3833)
| MODE | Frequency | Percent | Cumulative Frequency | Cumulative Percent |
|---|---|---|---|---|
| HBsAg (+) | 13 | 0.34 | 13 | 0.34 |
| HBsAg (+) and HBeAg (+) | 1 | 0.03 | 14 | 0.37 |
| HBsAg (+) and HBeAg (+) and Anti-HBc (+) | 20 | 0.52 | 34 | 0.89 |
| HBsAg (+) and Anti-HBe (+) and Anti-HBc (+) | 69 | 1.80 | 103 | 2.69 |
| HBsAg (+) and Anti-HBc (+) | 45 | 1.17 | 148 | 3.86 |
| Anti-HBs (+) | 471 | 12.29 | 1169 | 30.50 |
| Anti-HBc (+) | 499 | 13.02 | 698 | 18.21 |
| Anti-HBe (+) | 35 | 0.91 | 3706 | 96.69 |
| Anti-HBs (+) and Anti-HBc (+) | 782 | 20.40 | 3660 | 95.49 |
| Anti-HBs (+) and Anti-HBe (+) | 11 | 0.29 | 3671 | 95.77 |
| Anti-HBe (+) and Anti-HBc (+) | 51 | 1.33 | 199 | 5.19 |
| None | 1709 | 44.59 | 2878 | 75.08 |
| Other | 127 | 3.31 | 3833 | 100.00 |
HBsAg, hepatitis B surface antigen; anti-HBs, antibody to hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HBe, antibody to HBeAg; anti-HBc, antibody to hepatitis B core antigen.
Figure 1Seroprevalence of HBV markers in Northeast China by age groups
Prevalence of HBV Markers According to Sociodemographic Variables in the Jilin, China (n=3833)
| Parameters | N | HBsAg, n (%) | Anti-HBc, n (%) | Immune by vaccination, n (%) | Immune by exposure, n (%)a | |
|---|---|---|---|---|---|---|
| Drinking | No | 2532 | 102 (4.03) | 1051 (41.51) | 316 (12.37) | 603 (23.87) |
| Yes | 1301 | 66 (5.07) | 516 (39.66) | 155 (12.12) | 262 (20.18) | |
| P Value | NS | NS | NS | 0.0099 | ||
| Smoking | No | 2449 | 84 (3.43) | 905 (39.4) | 317 (12.94) | 554 (22.66) |
| Yes | 1384 | 84 (6.07) | 602 (43.5) | 154 (11.13) | 311 (22.55) | |
| P Value | 0.0001 | 0.0133 | NS | NS | ||
| Sleep quality | Bad | 915 | 57 (6.23) | 387 (42.3) | 98 (10.71) | 192 (21.06) |
| Good | 2918 | 111 (3.8) | 1180 (40.44) | 373 (12.78) | 673 (23.1) | |
| P Value | 0.0018 | NS | NS | NS | ||
| Family size | ≥5 people in house | 857 | 44(5.14) | 395(46.09) | 110(12.85) | 206(24.15) |
| <5 people in house | 2976 | 124(4.17) | 1172(39.38) | 361(12.13) | 659(22.64) | |
| P Value | NS | 0.0004 | NS | NS | ||
| Occupation | Peasant | 2277 | 104(4.57) | 924(40.58) | 277(12.17) | 521(23.93) |
| Laborer | 524 | 26(4.96) | 225(42.94) | 56(10.69) | 116(22.26) | |
| Small private businessmen | 278 | 22(7.91) | 122(43.38) | 25(8.99) | 63(21.74) | |
| Cadre officials | 754 | 16(2.12) | 293(39.26) | 113(14.99) | 165(21.88) | |
| P Value | 0.0004 | 0.0001 | 0.0271 | NS | ||
| Income | >800 RMB | 949 | 45(4.74) | 400(42.15) | 138(14.54) | 225(23.81) |
| ≤800 RMB | 2884 | 123(4.26) | 1167(40.46) | 333(11.55) | 640(22.23) | |
| P Value | NS | NS | 0.0146 | NS | ||
| Gender | Female | 2055 | 69(3.36) | 775(37.71) | 259(12.52) | 427(20.82) |
| Male | 1778 | 99(5.57) | 792(44.54) | 212(12.02) | 438(24.7) | |
| P Value | 0.0006 | 0.0001 | NS | 0.0042 | ||
| personal history of vaccination | No | 2691 | 146(5.1) | 970(34.2) | 194(6.8) | 306(11.4) |
| yes | 974 | 22(2.2) | 597(59.9) | 277(27.8) | 559(57.4) | |
| P Value | 0.001 | 0.001 | 0.001 | 0.001 | ||
| Family history of HBV | Yes | 572 | 106(18.5) | 273(47.7) | 79(13.8) | 119(20.8) |
| No | 3261 | 62(1.9) | 1294(39.7) | 392(12) | 746(22.9) | |
| P Value | 0.001 | 0.001 | NS | NS | ||
| Age (years) | 18-29 | 499 | 32(6.41) | 166(33.27) | 99(19.84) | 97(19.52) |
| 30-49 | 1749 | 79(4.52) | 677(38.71) | 184(10.52) | 371(21.29) | |
| 50-69 | 1478 | 56(3.78) | 658(44.52) | 179(12.11) | 362(24.51) | |
| 70 or older | 107 | 1(0.98) | 66(61.66) | 9(8.4) | 35(32.71) | |
| P Value | 0.0307 | 0.0001 | 0.0008 | 0.0033 |
NS: Not significant
a In the immunity by vaccination model, 9 patients had current infection for hepatitis B (HBsAg positive) and were excluded from the analysis.
Comparison of Biochemical Data between Different Groups According to HBsAg and HBeAg Status (n=3615)
| n | Abnormal ALT test,n (%) | Abnormal AST test, n(%) | Abnormalγ-GT test, n(%) | |
|---|---|---|---|---|
| HBsAg (+) subjects | 168 | 40 (23.81)* | 29 (17.26)* | 13 (7.7) |
| HBsAg (-) subjects | 3447 | 320 (9.28) | 183 (5.3) | 200 (5.8) |
| HBsAg (+)and HBeAg (+)subjects | 24 | 11 (45.83)** | 8 (33.33)** | 4 (16.7) |
| HBsAg (+)and HBeAg (-)subjects | 144 | 29 (20.14) | 21 (14.58) | 9 (6.3) |
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GTP, γ-glutamyl transpeptidase.
*P <0.001 vs HBsAg (-) subjects, ** P <0.001 vs HBsAg (-)and HBeAg (-) subjects
Multivariate Analyses of Risk Factors for Serological Evidence of Immunity Among Study Participants
| HBsAg seropositivity | Anti-HBc seropositivity | Immunity by vaccination | Immune by exposure | ||
|---|---|---|---|---|---|
| Parameters | Odds ratios with 95% confidence intervals | ||||
| Drinking | Yes | 0.58*(0.47-0.72) | |||
| No | 1.00 (reference) | ||||
| Smoking | Yes | 1.61*(1.13-2.29) | |||
| No | 1.00 (reference) | ||||
| Sleep equality | Bad | 1.79*(1.27-2.524) | |||
| Good | 1.00 (reference) | ||||
| Family size | ≥5 people in house | 1.35*(1.14-1.60) | |||
| <5 people in house | 1.00 (reference) | ||||
| Occupation | Peasant | 2.25*(1.12-4.50) | 1.11(0.86-1.42) | 0.95(0.66-1.369) | |
| Laborer | 2.26*(1.14-4.48) | 1.22(0.95-1.58) | 0.73(0.50-1.07) | ||
| Private small-businessman | 3.17*(1.56-6.43) | 1.39*(1.03-1.88) | 0.55*(0.33-0.89) | ||
| Cadre officials | 1.00 (reference) | ||||
| Income | >800 RMB | 1.30*(1.20-1.69) | |||
| ≤800 RMB | 1.00 (reference) | ||||
| personal history of vaccination | No | 1.00 (reference) | |||
| yes | 0.49*(0.21-0.58) | 3*(2.2-3.4) | 6.2*(4.9-6.31) | 4.2*(3.5-5.6) | |
| Family history of HBV | Yes | 2.41*(2.10-2.71) | 1.38*(1.16-1.65) | ||
| No | 1.00 (reference) | ||||
| Gender | Male | 1.79*(1.21-2.68) | 1.61*(1.36-1.90) | 1.64*(1.35-1.99) | |
| Female | 1.00 (reference) | ||||
| Age (years) | 18-29 | 1.00 (reference) | |||
| 30-49 | 0.65(0.41-1.00) | 1.35*(1.09-1.67) | 0.46*(0.35-0.61) | 1.17(0.91-1.51) | |
| 50-69 | 0.488*(0.30-0.78) | 1.64*(1.32-2.05) | 0.55*(0.41-0.72) | 1.39*(1.07-1.80) | |
| 70 or older | 0.15*(0.02-0.85) | 3.33*(2.14-5.17) | 0.35*(0.17-0.73) | 2.02*(1.26-3.23) | |
CI: Confidence interval. *P <0.001 vs reference
Immunity by exposure: anti-HBc (+) and anti-HBs (+); Immunity by vaccination: anti-HBc (-) and anti-HBs (+);
Risk for HBsAg and HBeAg Seropositivity Relative to Biochemical Markers among Study Participants
| OR(95% CI) | |||
|---|---|---|---|
| Abnormal ALT test | Abnormal AST test | Abnormal γ-GT test | |
| HBsAg (+) subjects | 2.66(1.80-3.05) | 3.88(2.62-4.15) | 1.06(0.52-1.46) |
| HBsAg (-) subjects | 1(reference) | ||
| HBsAg (+) and HBeAg (+) subjects | 3.12(2.12-4.05) | 2.81(2.01-3.79) | 1.14(0.35-4.50) |
| HBsAg (+) and HBeAg (-) subjects | 1(reference) | ||
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GTP, γ-glutamyl transpeptidase;
Odds ratios with 95% confidence intervals were adjusted for region of residence, drinking, smoking, sleep quality, blood transfusion, blood donation, family size, ethnicity, occupation, education level, income, gender, BMI, age, fatty liver, and hyperlipidemia.